Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease by C et al

We appreciate the comments by Shanoj et al 1 in response to our letter regarding the SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.2 Examining whether patients treated with CD20 inhibitors have antibody responses to SARS-CoV-2 is a question of great clinical importance in the management and vaccination of patients taking these medications during the COVID-19 pandemic.

Shanoj et al describe anti-spike and anti-nucleocapsid antibody test results among five patients with PCR-confirmed COVID-19 and prior exposure to rituximab.1 Among these patients, one patient developed neither anti-spike nor anti-nucleocapsid antibodies.1 This patient had been treated with rituximab for several years and had no detectable CD19+ B cells shortly before the onset of COVID-19.1 One patient developed anti-spike but not anti-nucleocapsid antibodies; although the duration of rituximab treatment is not provided, …

留言 (0)

沒有登入
gif